Renaissance Technologies LLC Invests $4.05 Million in Novavax, Inc. $NVAX

Renaissance Technologies LLC acquired a new position in shares of Novavax, Inc. (NASDAQ:NVAX) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 497,383 shares of the biopharmaceutical company’s stock, valued at approximately $4,049,000. Renaissance Technologies LLC owned 0.30% of Novavax as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Quarry LP bought a new stake in Novavax during the third quarter valued at $33,000. Duncker Streett & Co. Inc. grew its holdings in Novavax by 917.3% during the 1st quarter. Duncker Streett & Co. Inc. now owns 4,242 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 3,825 shares during the period. KBC Group NV raised its position in shares of Novavax by 34.9% in the 1st quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,229 shares in the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of Novavax in the 4th quarter worth about $33,000. Finally, Danske Bank A S acquired a new position in shares of Novavax in the 3rd quarter valued at about $64,000. Institutional investors own 53.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on NVAX. Wall Street Zen lowered Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. BTIG Research reissued a “buy” rating and issued a $19.00 price target on shares of Novavax in a research note on Thursday, June 11th. Zacks Research raised Novavax from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 6th. Weiss Ratings restated a “sell (d)” rating on shares of Novavax in a report on Tuesday. Finally, TD Cowen raised their price objective on shares of Novavax from $8.00 to $9.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $13.00.

Novavax Stock Up 2.7%

Shares of NVAX opened at $7.95 on Friday. Novavax, Inc. has a 12-month low of $6.20 and a 12-month high of $11.97. The business’s fifty day moving average is $8.72 and its 200 day moving average is $8.97. The stock has a market cap of $1.31 billion, a P/E ratio of -5.23 and a beta of 2.46.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The business had revenue of $56.70 million during the quarter, compared to analyst estimates of $52.51 million. During the same quarter in the previous year, the business posted $0.62 EPS. Novavax’s quarterly revenue was down 76.2% on a year-over-year basis. On average, analysts expect that Novavax, Inc. will post -0.31 EPS for the current year.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a second-quarter adjusted loss of $0.32 per share, better than the expected $0.38 loss, while revenue of $56.7 million exceeded estimates of approximately $52.5 million. NVAX Q2 Earnings & Sales Beat Estimates, 2026 Sales Outlook Raised
• Positive Sentiment: The company raised its full-year 2026 adjusted revenue framework to $235 million-$275 million from $230 million-$270 million and reduced combined GAAP research and development and selling, general and administrative expense guidance by $10 million at the midpoint. Novavax Raises 2026 Outlook After Q2 Beat
• Positive Sentiment: Novavax said completion of its manufacturing technology transfer to Sanofi is expected in mid-2027, potentially triggering a $75 million milestone payment. Sanofi also plans to advance discussions with regulators regarding timing for its Phase 3 COVID-19 and influenza combination-vaccine trial. Novavax Lifts Annual Revenue Forecast
• Neutral Sentiment: Novavax ended June with approximately $724 million in cash, cash equivalents, marketable securities and restricted cash. It also highlighted partner-led Matrix-M projects and plans to move its C. difficile vaccine program into clinical development as early as 2027. Novavax Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Revenue fell approximately 76% from the prior-year quarter to $56.7 million, product sales were only $19 million, and Novavax posted a $53 million net loss versus $107 million of net income a year earlier. The results underscore the company’s dependence on licensing revenue and milestone payments as vaccine demand wanes. Novavax Q2 Revenue Falls 76 Percent

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.